Petition Piles Pressure On FDA Over Biosimilar Suffix
Executive Summary
A citizen petition filed by biosimilars industry veteran Sarfaraz Niazi has once again urged the FDA to reconsider its approach on biosimilar naming, along with suggesting changes to language used by the regulator to describe biosimilars.
You may also be interested in...
US Biosimilar Market – Who's In It For The Long Haul?
A biopharma conference in Mumbai hears how the US biosimilars landscape could potentially change over the long term when deep price cuts set in and payers have a greater say in matters. Might big pharma consider pulling out?
FTC Warns FDA That Biologic Suffixes Will Curb Competition
The US Food and Drug Administration should abandon its suffix-based naming proposals for biosimilars, according to local competition regulator the Federal Trade Commission, citing a dampening effect on the market and the likelihood of confusion.
FDA Must Do More To Counter Misinformation On Biosimilars
More should be done by the FDA to counter misinformation perpetuated by originators over biosimilars, the AAM and its Biosimilars Council have urged in comments attached to a citizen petition lodged by Pfizer.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: